Expression of RFC/SLC19A1 is Associated with Tumor Type in Bladder Cancer Patients
Open Access
- 8 July 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7), e21820
- https://doi.org/10.1371/journal.pone.0021820
Abstract
Urinary bladder cancer (UBC) ranks ninth in worldwide cancer. In Egypt, the pattern of bladder cancer is unique in that both the transitional and squamous cell types prevail. Despite much research on the topic, it is still difficult to predict tumor progression, optimal therapy and clinical outcome. The reduced folate carrier (RFC/SLC19A1) is the major transport system for folates in mammalian cells and tissues. RFC is also the primary means of cellular uptake for antifolate cancer chemotherapeutic drugs, however, membrane transport of antifolates by RFC is considered as limiting to antitumor activity. The purpose of this study was to compare the mRNA expression level of RFC/SLC19A1 in urothelial and non-urothelial variants of bladder carcinomas. Quantification of RFC mRNA in the mucosa of 41 untreated bladder cancer patients was performed using RT-qPCR. RFC mRNA steady-state levels were ∼9-fold higher (N = 39; Pvs. non-urothelial; pvs. non-muscle invasive) implying that RFC cannot be used for prognostic purposes in bladder carcinomas and its increased expression is an early event in human bladder tumors pathogenesis. Further, RFC can be considered as a potential marker for predicting response to antifolate chemotherapy in urothelial carcinomas.Keywords
This publication has 32 references indexed in Scilit:
- LitInspector: literature and signal transduction pathway mining in PubMed abstractsNucleic Acids Research, 2009
- The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR ExperimentsClinical Chemistry, 2009
- The present and future burden of urinary bladder cancer in the worldWorld Journal of Urology, 2009
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Human reduced folate carrier: translation of basic biology to cancer etiology and therapyCancer and Metastasis Reviews, 2007
- Molecular basis of antifolate resistanceCancer and Metastasis Reviews, 2007
- Impaired CREB-1 Phosphorylation in Antifolate-Resistant Cell Lines with Down-Regulation of the Reduced Folate Carrier GeneMolecular Pharmacology, 2004
- Alterations in the Expression of Transcription Factors and the Reduced Folate Carrier as a Novel Mechanism of Antifolate Resistance in Human Leukemia CellsPublished by Elsevier BV ,2003
- Molecular, biochemical, and cellular pharmacology of pemetrexedSeminars in Oncology, 2002
- BILHARZIAL RELATED, ORGAN CONFINED, MUSCLE INVASIVE BLADDER CANCER: PROGNOSTIC VALUE OF APOPTOSIS MARKERS, PROLIFERATION MARKERS, p53, E-CADHERIN, EPIDERMAL GROWTH FACTOR RECEPTOR AND c-erbB-2Journal of Urology, 2001